
Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Data Showing Consistent Efficacy Signals for Remlifanserin in Alzheimer’s Disease Psychosis
Acadia Pharmaceuticals has presented additional findings from its Phase 2 RADIANT clinical trial evaluating remlifanserin as a potential treatment for hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). The new analyses were shared during an oral presentation at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, Massachusetts, providing further information about the investigational therapy’s efficacy, safety and tolerability.
The presentation builds on previously announced topline results from the RADIANT study. The latest analyses indicate that once-daily remlifanserin at a 60 mg dose demonstrated a consistent treatment effect across multiple measures of psychosis and at several assessment timepoints. The findings also provided additional insights into the relationship between patients’ baseline psychosis severity and the estimated treatment effect.
The Phase 2 study evaluated two doses of remlifanserin, 30 mg and 60 mg, against placebo. Although the 60 mg dose narrowly missed the primary efficacy endpoint at Week 6, it demonstrated a numerical improvement compared with placebo on the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions (SAPS-H+D). The higher dose also achieved nominal statistical significance on the key secondary endpoint, the Clinical Global Impression-Severity of Alzheimer’s Disease Psychosis (CGI-S-ADP).
The 30 mg dose demonstrated minimal efficacy compared with placebo, supporting the observation of a dose-response relationship in the study. Additional analyses presented at CTAD further explored the performance of the 60 mg dose across other clinical assessment tools, including measures of overall clinical improvement and neuropsychiatric symptoms.
Acadia said the new findings add to the evidence supporting continued clinical development of remlifanserin. The company is advancing the Phase 3 portion of the RADIANT clinical program for Alzheimer’s disease psychosis and is also evaluating the therapy in a separate Phase 2 study involving patients with Lewy body dementia psychosis.
Additional Analyses Build on Phase 2 RADIANT Results
Alzheimer’s disease psychosis is associated with symptoms such as hallucinations and delusions, which can create significant challenges for patients, caregivers and healthcare professionals. These symptoms may complicate disease management and add to the care requirements of people living with Alzheimer’s disease.
Remlifanserin is an investigational therapy being developed by Acadia Pharmaceuticals to address hallucinations and delusions associated with Alzheimer’s disease psychosis. The Phase 2 RADIANT trial was designed to evaluate its efficacy, safety and tolerability in this patient population.
The previously reported topline findings showed that once-daily remlifanserin 60 mg produced a 2.2-point greater improvement than placebo on the SAPS-H+D Total Score at Week 6. The difference was reflected in a treatment effect of −2.2 points, with a p-value of 0.0603. Although this result narrowly missed the study’s primary endpoint, the higher dose achieved nominal statistical significance on the key secondary endpoint, CGI-S-ADP, with a p-value of 0.0077.
The 30 mg dose showed minimal efficacy compared with placebo. The difference between the two doses supported a potential dose-response pattern, with the 60 mg dose demonstrating a more pronounced treatment effect across the reported measures.
The additional CTAD analyses examined whether this pattern was also evident across other psychosis assessments and at different points during treatment. The findings showed that the 60 mg dose was favored over placebo on several measures, including the Clinical Global Impression-Improvement of Alzheimer’s Disease Psychosis (CGI-I-ADP), the Neuropsychiatric Inventory (NPI) and the Neuropsychiatric Inventory Nursing Home version (NPI-NH).
These additional measures are important because they assess different aspects of patients’ symptoms and clinical status. Considering several assessment tools can provide a broader understanding of treatment response than relying on a single endpoint.
CGI-I-ADP Results Show Improvement Across Multiple Timepoints
One of the key findings presented at CTAD involved the CGI-I-ADP assessment. This measure evaluates the overall clinical improvement of patients with Alzheimer’s disease psychosis during treatment.
In the new analyses, remlifanserin 60 mg was favored over placebo at Weeks 2, 4 and 6. The reported nominal p-values were:
- Week 2: p=0.0232
- Week 4: p=0.0082
- Week 6: p=0.0208
The results showed a treatment effect across all three assessment timepoints, suggesting that differences between the 60 mg dose and placebo were observed during the six-week treatment period.
The Week 6 results also examined the proportion of patients whose clinical condition was rated as improved or very much improved. Among patients receiving remlifanserin 60 mg, 44.0% achieved a CGI-I-ADP score of 1 or 2, indicating that they were considered improved or very much improved.
In comparison, 31.8% of patients in the placebo group achieved the same level of improvement.
This difference provides another perspective on the clinical response observed in the study. Rather than evaluating only changes in symptom scores, the CGI-I-ADP assessment considers the clinician’s overall impression of how a patient’s condition has changed during treatment.
The findings were presented as additional analyses and the reported p-values were nominal. They should therefore be interpreted in the context of the overall Phase 2 study results, including the fact that the primary endpoint was narrowly missed.
Improvements Observed on NPI and NPI-NH Psychosis Measures
The CTAD presentation also included findings from the Neuropsychiatric Inventory and its Nursing Home version. These assessment tools are used to evaluate behavioral and psychological symptoms associated with neurological conditions, including Alzheimer’s disease.
For the psychosis score, remlifanserin 60 mg separated from placebo at Week 4, with a nominal p-value of 0.0084. The difference remained evident at Week 6.
At the six-week assessment, the least-squares mean change in the NPI/NPI-NH psychosis score was −7.3 among patients receiving remlifanserin 60 mg, compared with −5.9 among those receiving placebo. The difference was statistically significant on a nominal basis, with a p-value of 0.0385 and an effect size of 0.29.
The reported results indicate a greater numerical reduction in psychosis scores in the 60 mg treatment group than in the placebo group. The effect size provides an additional measure of the difference between the groups and helps characterize the magnitude of the observed treatment effect.
The NPI and NPI-NH assessments provide information about neuropsychiatric symptoms that may affect patients’ daily lives and care requirements. Hallucinations and delusions can be particularly difficult for individuals with Alzheimer’s disease and those supporting their care. Evaluating these symptoms through established clinical measures can help researchers understand whether an investigational treatment is associated with changes in psychosis-related behaviors.
The Week 4 and Week 6 findings add to the CGI-I-ADP results, showing that the 60 mg dose was favored across more than one assessment approach.
CGI-S-ADP Findings Support the Higher-Dose Treatment Effect
Additional findings were also reported for the Clinical Global Impression-Severity of Alzheimer’s Disease Psychosis assessment.
The CGI-S-ADP scale evaluates the severity of psychosis symptoms in patients with Alzheimer’s disease. It provides a clinician-rated assessment of the overall severity of the condition.
In the new analyses, remlifanserin 60 mg separated from placebo at Week 4, with a nominal p-value of 0.0107. The difference was also observed at Week 6, consistent with the previously reported nominally significant result on the key secondary endpoint.
The original Phase 2 findings showed a p-value of 0.0077 for CGI-S-ADP at Week 6. The additional Week 4 result provides further information about the timing of the observed treatment effect.
Together with the CGI-I-ADP and NPI/NPI-NH findings, the results indicate that the higher dose demonstrated a consistent efficacy signal across multiple clinical measures. However, the primary SAPS-H+D endpoint remains an important consideration when interpreting the overall outcome of the Phase 2 study.
Baseline Psychosis Severity May Influence Estimated Treatment Effect
Another important component of the CTAD presentation involved analyses examining the relationship between baseline psychosis severity and the estimated treatment effect of remlifanserin.
The new analyses showed that the estimated treatment effect on the SAPS-H+D Total Score increased across progressively higher baseline psychosis severity thresholds.
This finding suggests that the difference between remlifanserin and placebo may have been greater among patients entering the study with more severe psychosis symptoms. The observation provides a potential area for further investigation as the company advances the therapy into Phase 3 development.
Baseline disease severity can be an important consideration in clinical research because patients may respond differently to treatment depending on their initial symptom burden. Examining outcomes across severity levels can help researchers better understand whether particular patient groups demonstrate different treatment patterns.
The findings do not establish a definitive patient subgroup that will benefit most from remlifanserin. Instead, they provide additional information that may help inform future clinical development and the design of subsequent studies.
Further evaluation will be required to determine whether the relationship between baseline psychosis severity and treatment effect is replicated in larger Phase 3 populations.
Acadia Highlights Safety and Tolerability Findings
In addition to efficacy, Acadia reported that the safety and tolerability profile of remlifanserin 60 mg was consistent with the previously announced topline findings.
The rates of treatment-emergent adverse events, drug-related adverse events, serious adverse events and discontinuations due to adverse events were similar to or lower than those reported in the placebo group.
The rates of treatment-emergent adverse events were 36.8% in the 60 mg remlifanserin group and 41.7% in the placebo group. Drug-related adverse events occurred in 5.6% of patients receiving the higher dose, compared with 7.8% of those receiving placebo.
Serious adverse events were reported in 1.6% of patients in the 60 mg group and 2.6% of patients in the placebo group. Discontinuations due to adverse events were also similar, occurring in 2.4% of patients receiving remlifanserin 60 mg and 2.6% of those receiving placebo.
Acadia also reported that there were no deaths in either remlifanserin treatment arm during the study.
These findings provide information about the therapy’s tolerability during the Phase 2 evaluation. As with all investigational medicines, additional safety information will be needed from larger and longer-duration studies to further characterize the treatment’s safety profile.
No Negative Impact Reported on Motor Symptoms or Cognition
The company also reported findings from assessments of motor symptoms and cognitive function.
According to Acadia, treatment with remlifanserin did not demonstrate a negative impact on motor symptoms compared with placebo, based on the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A).
The ESRS-A is used to evaluate extrapyramidal symptoms, which can include movement-related effects such as tremors, rigidity and other motor abnormalities. Monitoring these symptoms is relevant when assessing therapies for people with neurological conditions, particularly older adults who may already experience movement-related challenges.
The study also found no negative impact on cognition compared with placebo, based on the Mini-Mental State Examination (MMSE). This assessment is commonly used to evaluate cognitive function, including areas such as memory, attention and orientation.
Cardiac safety monitoring also formed part of the study evaluation. Acadia reported that no patient assessed had a corrected QT interval using Fridericia’s formula (QTcF) above 480 milliseconds or an increase exceeding 60 milliseconds.
The QTcF measurement is used to assess the heart’s electrical activity and identify potential changes in the interval associated with cardiac rhythm risk. The reported findings provide additional information about the cardiac safety observations in the Phase 2 trial.
Management Comments on the New Findings
Sanjeev Pathak, M.D., Senior Vice President and Head of Clinical Development at Acadia Pharmaceuticals, said the new analyses strengthen the evidence of a consistent efficacy signal with once-daily remlifanserin 60 mg across multiple measures of psychosis and different assessment timepoints.
Pathak also highlighted the observed dose-response pattern and the new findings relating baseline psychosis severity to the estimated treatment effect.
According to him, these observations further reinforce the company’s confidence in the potential activity of remlifanserin as it continues the Phase 3 development program.
The comments reflect Acadia’s interpretation of the additional Phase 2 findings. The company is continuing to evaluate the investigational therapy to determine whether the observed efficacy patterns can be confirmed in later-stage clinical studies.
Phase 3 Development for Alzheimer’s Disease Psychosis Continues
Based on the Phase 2 RADIANT findings, Acadia Pharmaceuticals is advancing the Phase 3 portion of the clinical program evaluating remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis.
The additional CTAD analyses provide further information for the ongoing development program, particularly regarding the higher 60 mg dose, the consistency of treatment effects across multiple clinical measures and the possible relationship between baseline psychosis severity and treatment response.
The primary endpoint result from Phase 2 remains an important factor in assessing the therapy’s clinical evidence. Although the 60 mg dose narrowly missed the primary SAPS-H+D endpoint, the findings across secondary and additional measures provide information that can guide further investigation.
Phase 3 studies will be important for determining whether the treatment effects observed in the Phase 2 trial can be replicated in larger patient populations and whether the safety and tolerability profile remains consistent during further evaluation.
Separate Phase 2 Study Evaluating Lewy Body Dementia Psychosis
Beyond its Alzheimer’s disease psychosis program, Acadia is also investigating remlifanserin in a separate Phase 2 clinical study involving patients with Lewy body dementia psychosis.
The additional study is designed to evaluate the therapy’s efficacy, safety and tolerability in this distinct patient population.
Lewy body dementia is a neurodegenerative condition that can involve cognitive changes, movement symptoms and psychiatric manifestations. Psychosis-related symptoms, including hallucinations and delusions, can form part of the disease experience and create challenges for patients and caregivers.
By evaluating remlifanserin in both Alzheimer’s disease psychosis and Lewy body dementia psychosis, Acadia is exploring its potential application across two neurological conditions associated with psychosis.
The Lewy body dementia study remains separate from the RADIANT program, and its results will be needed to assess the investigational therapy in that population.
Continued Evaluation of Remlifanserin
Acadia’s latest presentation at CTAD 2026 adds further detail to the Phase 2 RADIANT findings. The new analyses showed that once-daily remlifanserin 60 mg was favored over placebo across several psychosis measures and assessment timepoints, including CGI-I-ADP, NPI/NPI-NH and CGI-S-ADP.
The study also reported an average treatment difference of −2.2 points versus placebo on the primary SAPS-H+D endpoint at Week 6, although the result narrowly missed statistical significance. The higher dose achieved nominal significance on the key secondary endpoint, while the 30 mg dose demonstrated minimal efficacy compared with placebo.
The safety findings showed similar or lower rates of several adverse-event categories compared with placebo, with no reported deaths in either remlifanserin treatment arm. Acadia also reported no negative impact on motor symptoms or cognition compared with placebo and no patient with a QTcF above 480 milliseconds or an increase greater than 60 milliseconds.
With Phase 3 development for Alzheimer’s disease psychosis underway and a separate Phase 2 study evaluating Lewy body dementia psychosis, Acadia is continuing to investigate remlifanserin as a potential treatment for psychosis associated with neurodegenerative diseases. The ongoing clinical program will provide additional evidence needed to determine the therapy’s efficacy, safety and potential role in treating patients experiencing hallucinations and delusions.
About RADIANT
RADIANT is a global, multi-center, randomized, double-blind, placebo-controlled, operationally seamless Phase 2 and 3 clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). The Phase 2 portion of the program was designed to evaluate the efficacy, safety, and tolerability of remlifanserin at 60 mg and 30 mg once-daily doses compared with placebo. Patients who complete any of the RADIANT studies have the option of participating in a long-term open-label extension (OLE) study.
About Alzheimer’s Disease Psychosis
According to the Alzheimer’s Association, more than 7 million people aged 65 years and older in the United States are living with Alzheimer’s disease (AD).1,2 Approximately 30% of patients with AD experience psychosis, commonly consisting of hallucinations and delusions.3,4 These symptoms may be frequent and may recur over time.5
A hallucination is defined as a perception-like experience that occurs without an external stimulus and is sensory (seen, heard, felt, tasted, sensed, smelled) in nature. A delusion is defined as a false, fixed belief despite evidence to the contrary.6 Psychosis in patients with dementia is associated with outcomes such as increased likelihood of nursing home placement, more severe dementia, and increased risk of morbidity and mortality.7,8 There is no FDA-approved drug for the treatment of Alzheimer’s disease psychosis.
About Remlifanserin
Remlifanserin is a novel, highly selective 5HT2A receptor inverse agonist being developed to treat Alzheimer’s disease psychosis and Lewy body dementia psychosis.
About Acadia Pharmaceuticals
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs.


